Abstract
Post-epilepsy surgery antiepileptic drug discontinuation (AED) practices remain unclear and little evidence about the optimum timing exists. In the present study, we reviewed the types of surgery for epilepsy and their outcome. The current concepts for discontinuation of AED after surgery are presented and all contributing factors that should be taken into consideration are discussed.
Keywords: Epilepsy surgery, anti-epileptic drug, outcome, epilepsy, seizure, treatment.
Current Pharmaceutical Design
Title:AED Strategy after Refractory Epilepsy Surgery
Volume: 23 Issue: 42
Author(s): Andreas Zigouris, George A. Alexiou*, Marios S. Themistocleous and Spyridon Voulgaris
Affiliation:
- Department of Neurosurgery, University Hospital of Ioannina, Ioannina,Greece
Keywords: Epilepsy surgery, anti-epileptic drug, outcome, epilepsy, seizure, treatment.
Abstract: Post-epilepsy surgery antiepileptic drug discontinuation (AED) practices remain unclear and little evidence about the optimum timing exists. In the present study, we reviewed the types of surgery for epilepsy and their outcome. The current concepts for discontinuation of AED after surgery are presented and all contributing factors that should be taken into consideration are discussed.
Export Options
About this article
Cite this article as:
Zigouris Andreas, Alexiou A. George*, Themistocleous S. Marios and Voulgaris Spyridon, AED Strategy after Refractory Epilepsy Surgery, Current Pharmaceutical Design 2017; 23 (42) . https://dx.doi.org/10.2174/1381612823666171030154449
DOI https://dx.doi.org/10.2174/1381612823666171030154449 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Pharmacokinetics of Levetiracetam in Neonates
Current Drug Metabolism β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Current Drug Abuse Reviews Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Old Weapons for New Wars: Bioactive Molecules From Cnidarian Internal Defense Systems
Central Nervous System Agents in Medicinal Chemistry Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Molecular Targets of Cannabinoids Associated with Depression
Current Medicinal Chemistry Intracerebrally Applied Botulinum Neurotoxin in Experimental Neuroscience
Current Pharmaceutical Biotechnology The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is Not Always Enough
Current Topics in Medicinal Chemistry Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Current Drug Safety Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry New Anticonvulsant Agents
Current Topics in Medicinal Chemistry Subject Index to Volume 1
Current Neurovascular Research Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design